Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unspecified Adult Solid Tumor, Protocol Specific: early-phase trial registry
5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #115 of 28,707 conditions by registered trial count.
112 US clinical trials · 5 currently recruiting · #115 of 28,707 conditions by registered trial count
Unspecified Adult Solid Tumor, Protocol Specific: 112 US clinical trials tracked, 5 recruiting.
Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.
Enrollment posture brief
Registry condition unspecified-adult-solid-tumor-protocol-specific
OPEN 5 | RECR 4% | LATE 10 | EARLY 93 | RANK #115 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Attention Deficit Disorder With Hyperactivity (5% recruiting · 21 trials)
Unspecified Adult Solid Tumor, Protocol Specific lists 5 open slots (4% of 112 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unspecified Adult Solid Tumor, Protocol Specific on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unspecified Adult Solid Tumor, Protocol Specific is recruiting below its size-band peers.
5 of 112 indexed trials (4.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unspecified Adult Solid Tumor, Protocol Specific research.
National Cancer Institute (NCI) accounts for 26 of 112 trials (23.2%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Unspecified Adult Solid Tumor, Protocol Specific trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 84 trials that report a genuine target (sentinel values excluded). 66 of those (78.6%) plan for fewer than 100 participants.
-
Unspecified Adult Solid Tumor, Protocol Specific research is mostly interventional.
107 interventional and 5 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
112 total, page 3 of 3
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Vion Pharmaceuticals
NCT00049699
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
National Cancer Institute (NCI)
NCT00072111
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
OSI Pharmaceuticals
NCT00033241
S-3304 in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
NCT00033566
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
City of Hope Medical Center
NCT00004243
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT00003038
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors
University of Rochester
NCT00004016
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
NCT00006083
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
Mayo Clinic
NCT00046904
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Northwestern University
NCT00004913
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
NCT00003368
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
City of Hope Medical Center
NCT00006257
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 8 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Unspecified Adult Solid Tumor, Protocol Specific records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unspecified Adult Solid Tumor, Protocol Specific trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unspecified Adult Solid Tumor, Protocol Specific page
112 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Unspecified Adult Solid Tumor, Protocol Specific trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unspecified Adult Solid Tumor, Protocol Specific condition card totals 112 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.